Drug Profile
Research programme: eye disorder therapeutics - Johnson & Johnson Innovative Medicine/University of Massachusetts
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator University of Massachusetts Amherst
- Developer Johnson & Johnson Innovative Medicine; University of Massachusetts Amherst
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Feb 2021 No recent reports of development identified for research development in Eye-disorders in USA
- 05 Jan 2017 Janssen Pharmaceuticals enters into a licensing agreement with the University of Massachusetts to develop therapeutics for eye disorders